Antiviral therapy for hepatitis virus-related hepatocellular carcinoma: current status and challenges
The incidence rate of hepatocellular carcinoma (HCC) is increasing around the world and tends to decrease in East Asia and several regions in China; however, China still has higher incidence rate and mortality rate of HCC than most countries. Studies have shown that long-term antiviral therapy can i...
Main Authors: | DONG Jing, JIANG Jiaji |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Department of Journal of Clinical Hepatology
2017-07-01
|
Series: | Linchuang Gandanbing Zazhi |
Online Access: | http://www.lcgdbzz.org/qk_content.asp?id=8312 |
Similar Items
-
Explanation of the “Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma”
by: DONG Jing
Published: (2013-01-01) -
Explanation of the “Expert consensus on antiviral therapy to hepatitis B/C virus-related hepatocellular carcinoma”
by: DONG Jing
Published: (2014-07-01) -
Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies
by: Jonggi Choi, et al.
Published: (2021-04-01) -
Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma
by: Liver Cancer Study Group,Chinese Society of Hepatology,Chinese Medical Association
Published: (2013-01-01) -
Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy
by: Yang Ke, et al.
Published: (2013-09-01)